Stocks · News reference
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent decrease over losses of $(0.02) per share from the same
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
IGC Pharma, Inc. announced that the Canadian Intellectual Property Office has granted a patent for its investigational oral therapy, IGC-AD1, which is currently in Phase 2 clinical trials for treating agitation in Alzheimer's dementia.
Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.
https://www.marijuanamoment.net/federal-court-rejects-marijuana-opponents-request-to-block-trumps-rescheduling-move/
https://x.com/DougKass/status/2093394146182480247